A completed phase 1/2 study (NCT02327078) evaluated the safety, tolerability, and efficacy of another IDO inhibitor, i.e., epacadostat, when administered in combination with nivolumab, in various advanced cancer types, including melanoma. This evidence concerns the gene IDO1 and melanoma.